Ste Virbac SA

VIRP

Equity

ISIN FR0000031577 / Valor 524407

Euronext - Euronext Paris (2024-11-21)

EUR 319.50+0.47%

Ste Virbac SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Ste Virbac SA is a global company that provides a wide range of products and services to veterinarians, farmers, and pet owners in over 100 countries. Their innovative solutions cover various animal species and diseases, contributing to the advancement of animal health worldwide. Recently, the company completed the acquisition of Sasaeah, solidifying their leadership position in the farm animal vaccines market in Japan, particularly in the cattle segment, and expanding their portfolio of pharmaceutical products for all major species.

Summarized from source with an LLMView SourceSector: Healthcare

Quarterly Consolidated Revenue

Ste Virbac SA reported second-quarter revenue of €357.4 million, marking a significant increase of +21.8% at constant exchange rates compared to the same period in 2023.

Cumulative Consolidated Revenue

For the first half of 2024, Ste Virbac SA's revenue reached €703.1 million, up from €610.5 million in 2023, representing an overall change of +15.2%.

Regional Performance

The Europe zone contributed significantly to Ste Virbac SA's growth, with a +12.3% increase at constant exchange rates and scope, driven by a rebound in the dog and cat vaccine range and increased demand for petfood and pet care products.

Species Segment Growth

Ste Virbac SA's companion animal segment posted strong growth of +15.1% at constant exchange rates and scope, driven by dental, dermatology, petfood, and specialty product ranges, as well as increased production capacity for dog and cat vaccines.

Outlook for 2024

Ste Virbac SA has revised its forecasts for 2024, now anticipating revenue growth between 7% and 9% at constant exchange rates and scope, with an adjusted EBIT ratio of around 16%. The contribution from recent acquisitions is expected to add around +5.5 growth points to revenue.

Summarized from source with an LLMView Source

Key figures

15.1%1Y

-26.6%3Y

51.1%5Y

Performance

31.4%1Y

34.5%3Y

38.6%5Y

Volatility